Cyclin-dependent kinase 11 (CDK11) is crucial in the growth of liposarcoma cells

Cancer Lett. 2014 Jan 1;342(1):104-12. doi: 10.1016/j.canlet.2013.08.040.

Bin Jia ¹, Edwin Choy, Gregory Cote, David Harmon, Shunan Ye, Quancheng Kan, Henry Mankin, Francis Hornicek, Zhenfeng Duan

Affiliations

Affiliation

1 Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; Department of Pharmacology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.

PMID: 24007862 DOI: 10.1016/j.canlet.2013.08.040

Abstract

Liposarcoma is the second most common soft tissue sarcoma in adults, but treatment options have been quite limited thus far. In this study, we investigated the functional and therapeutic relevance of cyclin-dependent kinase 11 (CDK11) as a putative target in liposarcoma. CDK11 knockdown by synthetic siRNA or lentiviral shRNA decreased cell proliferation, and induced Apoptosis in liposarcoma cells. Moreover, CDK11 knockdown enhances the cytotoxic effect of doxorubicin to inhibit cell growth in liposarcoma cells. These findings suggest that CDK11 is critical for the growth and proliferation of liposarcoma cells. CDK11 may be a promising therapeutic target for the treatment of liposarcoma patients.

Keywords

CDK11; Immunohistochemistry; Kinase; Liposarcoma; Tissue microarray.

Name
Email *

	Sorry, but the email address you supplied was invalid.